logo
In unanimous decision, Supreme Court makes it easier for students with disabilities to sue schools

In unanimous decision, Supreme Court makes it easier for students with disabilities to sue schools

Yahoo2 days ago

WASHINGTON − A unanimous Supreme Court on June 12 made it easier for families to use the Americans with Disabilities Act to sue schools for damages, ruling a lower court used too tough a standard to dismiss a lawsuit from a student with a rare form of epilepsy.
Writing for the court, Chief Justice John Roberts said the student's family did not have to show the school acted in 'bad faith or gross misjudgment." That's more difficult to prove than the 'deliberate indifference' standard courts often use when weighing other types of disability discrimination claims.
The court also rejected an argument from the school that would have raised the bar for all victims of disability discrimination rather than lowered it for educational instruction claims.
The case, A.J.T. v. Osseo Area Schools, was closely watched by disability rights groups. They say the courts have created a 'nearly insurmountable barrier' for schoolchildren and their families.
But schools across the country worry that making lawsuits easier to win will create a more adversarial relationship between parents and schools in the difficult negotiations needed to balance a student's needs with a school's limited resources.
In this case, Gina and Aaron Tharpe said they spent years asking Osseo Area School District to accommodate their daughter's severe cognitive impairment and rare form of epilepsy called Lennox-Gastaut Syndrome. Her seizures are so frequent in the morning that she can't attend school before noon.
A previous school in Tennessee shifted Ava's school day so it started in the afternoon and ended with evening instruction at home.
But the Tharpes say the Minnesota school system, where she is currently enrolled, refused to provide the same adjustment. As a result, she received only 4.25 hours of instruction a day, about two-thirds of what nondisabled students received.
When the Tharpes sued under the ADA and the Rehabilitation Act of 1973, lower courts dismissed the case.
More: For students with disabilities, what's the difference between IEPs and 504 plans?
Judges on the St. Louis-based 8th U.S. Circuit Court of Appeals said their hands were tied because of a 1982 circuit decision – Monahan v. Nebraska − that said school officials need to have acted with 'bad faith or gross misjudgment' for suits to go forward involving educational services for children with disabilities.
The Tharpes 'may have established a genuine dispute about whether the district was negligent or even deliberately indifferent, but under Monahan, that's just not enough,' the appeals court said.
More: Will a Texas-led legal fight over gender dysphoria threaten disabled student protections?
Hundreds of district court decisions across the country have been litigated under that standard, with most of them ending in a loss for the families, according to the Tharpes' attorneys.
The Justice Department backed the Tharpes' argument that there should not be a different standard for disability discrimination cases involving education.
The school district's attorneys pushed the court to apply a tougher standard for all cases rather than lower the bar for cases like Ava's.
But because the school district didn't make that argument until after the court agreed to take the case, the justices said they could not consider it.
'We will not entertain the District's invitation to inject into this case significant issues that have not been fully presented,' Roberts wrote for the court.
Two justices said the school district raised an important issue that the court should consider in a future case.
'Whether federal courts are applying the correct legal standard is an issue of national importance, and the District has raised serious arguments that the prevailing standards are incorrect,' Justice Clarence Thomas wrote in a concurring opinion that was joined by Justice Brett Kavanaugh. 'That these issues are consequential is all the more reason to wait for a case in which they are squarely before us and we have the benefit of adversarial briefing.'
Ava's lawyers had warned that the school's argument threatened 'to eviscerate protections for every American who endures disability discrimination – and quite possibly other kinds of discrimination too.'
Roman Martinez, who represented the Tharpes, said the court's decision "gets the law exactly right, and it will help protect the reasonable accommodations needed to ensure equal opportunity for all."
'We are thrilled for Ava and her family," Martinez said in a statement.
The court's action revives, but does not settle, the Tharpes' lawsuit.
Attorneys for the district said the school had not shown 'deliberate indifference," the lower standard.
Although the school declined to provide after-school support at Ava's home, officials said they offered other measures to accommodate her needs while 'effectively utilizing scarce resources shared among all students, including others with disabilities.'
This article originally appeared on USA TODAY: Supreme Court makes it easier to sue schools in disability cases

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Yahoo

time34 minutes ago

  • Yahoo

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time35 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Yahoo

time35 minutes ago

  • Yahoo

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store